Our First targets

We’re making active immunotherapies for some of the most challenging diseases of our time

The immune system already holds the key to curing disease. We’re just unlocking it.

We're building the blueprint to end these diseases before they begin

Pipeline
We’ve built a healthy pipeline of assets
$60M invested in R&D behind the Ambifect® platform and Twilight’s pipeline
Our pipeline & platform can be applied to many diseases

Our pipeline & platform can be
applied many diseases

ALS / FTD
Chronic pain
Alzheimer's
COVID-19
Cancers
(breast, prostate, brain)
Cancer pain
Parkinson’s
MERS
Aging
Osteoarthritis
Lewy body dementia
Others
Chronic pain
Multiple sclerosis
ALS/FTD
Let's talk
We’re looking to partner with those who want to shape the future of immunotherapy.
Contact us